Gradient Investments LLC Grows Stock Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Share on StockTwits

Gradient Investments LLC raised its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 19.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,059 shares of the biopharmaceutical company’s stock after purchasing an additional 1,493 shares during the period. Gradient Investments LLC’s holdings in Alexion Pharmaceuticals were worth $887,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALXN. We Are One Seven LLC grew its stake in shares of Alexion Pharmaceuticals by 5.7% during the second quarter. We Are One Seven LLC now owns 1,586 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 86 shares during the last quarter. Signaturefd LLC grew its stake in shares of Alexion Pharmaceuticals by 13.2% during the second quarter. Signaturefd LLC now owns 822 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 96 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Alexion Pharmaceuticals by 6.5% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 1,810 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 111 shares during the last quarter. Verity Asset Management Inc. grew its stake in shares of Alexion Pharmaceuticals by 4.1% during the second quarter. Verity Asset Management Inc. now owns 2,842 shares of the biopharmaceutical company’s stock valued at $372,000 after buying an additional 112 shares during the last quarter. Finally, Vision Capital Management Inc. grew its stake in shares of Alexion Pharmaceuticals by 1.1% during the second quarter. Vision Capital Management Inc. now owns 10,482 shares of the biopharmaceutical company’s stock valued at $1,373,000 after buying an additional 113 shares during the last quarter. Institutional investors and hedge funds own 93.13% of the company’s stock.

NASDAQ ALXN opened at $99.25 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56. The stock has a market capitalization of $22.25 billion, a PE ratio of 14.00, a PEG ratio of 0.90 and a beta of 1.67. Alexion Pharmaceuticals, Inc. has a 1 year low of $92.56 and a 1 year high of $141.86. The business’s 50-day moving average is $103.91 and its 200 day moving average is $120.01.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.51. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. Alexion Pharmaceuticals’s quarterly revenue was up 15.1% on a year-over-year basis. During the same period last year, the firm earned $2.07 earnings per share. As a group, equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.05 earnings per share for the current year.

A number of research analysts have recently issued reports on the company. BMO Capital Markets assumed coverage on Alexion Pharmaceuticals in a research note on Thursday, September 12th. They set an “outperform” rating and a $149.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Alexion Pharmaceuticals in a research note on Wednesday, July 31st. They set an “overweight” rating and a $172.00 price objective on the stock. Citigroup set a $150.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 30th. Morgan Stanley reduced their price objective on Alexion Pharmaceuticals from $177.00 to $170.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Stifel Nicolaus reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Friday, August 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $159.76.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: What is Green Investing?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Anticipate Main Street Capital Co.  Will Announce Earnings of $0.63 Per Share
Brokerages Anticipate Main Street Capital Co. Will Announce Earnings of $0.63 Per Share
Scorum Coins  Trading 9.9% Lower  Over Last 7 Days
Scorum Coins Trading 9.9% Lower Over Last 7 Days
SelfSell Reaches Market Capitalization of $1.03 Million
SelfSell Reaches Market Capitalization of $1.03 Million
Kind Ads Token  Hits 24-Hour Volume of $28.00
Kind Ads Token Hits 24-Hour Volume of $28.00
$67.99 Million in Sales Expected for Franklin Covey Co.  This Quarter
$67.99 Million in Sales Expected for Franklin Covey Co. This Quarter
Cadence Design Systems Inc  Expected to Announce Quarterly Sales of $574.77 Million
Cadence Design Systems Inc Expected to Announce Quarterly Sales of $574.77 Million


© 2006-2019 Ticker Report